Response to the letter to the editor

Güner, Rahmet; Hasanoğlu, İmran; Kayaaslan, Bircan; Aypak, Adalet; Akıncı, Esragül; Bodur, Hürrem; Eser, Fatma; Kalem, Ayşe Kaya; Küçükşahin, Orhan; Ateş, İhsan; Baştuğ, Aliye; Tekçe, Yasemin Tezer; Bilgiç, Zeynep; Gursoy, Fahriye Melis; Akçalı, Hatice Nisa; İzdeş, Seval; Erdem, Deniz; Asfuroglu, Emra; Hezer, Habibe; Kılıç, Hatice; Civak, Musa; Aydoğan, Sibel; Buzğan, Turan

doi:10.1016/j.jiph.2021.12.007

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, favipavir was associated with longer hospitalization and increased risk of ICU admission and IMV requirement in our study population. In line with these findings, a retrospective study on 824 COVID-19 patients reported that ICU admission rates were significantly higher in patients treated with favipiravir (38). However, in their study evaluating the ICU admission rates of COVID-19 patients in two different time periods, i.e., before and after the addition of favipiravir, Guner et al found that the percentage of cases admitted to the ICU dropped, while the intubation rate among ICU patients decreased after favipiravir was implemented (39).…”

Section: Univariate Analyses Multi Variate Binary Logistic Regression...mentioning

confidence: 55%

The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort

Babayiğit¹,

Köktürk²,

Kül

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Background and objectivesAlthough several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity.MethodsPatients admitted to 26 different hospitals located in 16 different provinces between March 11–July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation.ResultsWe retrospectively evaluated 1,472 COVID-19 adult patients; 57.1% were men (mean age = 51.9 ± 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5–12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (β [95% CI]: 4.71 [2.31–7.11]; p = 0.001), favipiravir (β [95% CI]: 3.55 [2.56–4.55]; p = 0.001) and HCQ (β [95% CI]: 0.84 [0.02–1.67]; p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70–5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28–6.75]; p = 0.011).ConclusionOur findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.

show abstract

Section: Univariate Analyses Multi Variate Binary Logistic Regression...mentioning

confidence: 55%